[181 Pages Report] The Biosimilars Market size was estimated at USD 40.70 billion in 2023 and expected to reach USD 49.91 billion in 2024, at a CAGR 23.31% to reach USD 176.48 billion by 2030.
The FPNV Positioning Matrix is pivotal in evaluating the Biosimilars Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biosimilars Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
The report delves into recent significant developments in the Biosimilars Market, highlighting leading vendors and their innovative profiles. These include Alvotech, Amgen Inc., Apotex Inc., Biocon Limited, BioFactura, Inc., Biogen Inc., Boehringer Ingelheim International GmbH., Catalent, Inc, Celltrion Healthcare Co.,Ltd., Coherus BioSciences, Dr. Reddy's Laboratories Limited, Eden Biologics, Inc., F. Hoffmann-La Roche AG, Fresenius Kabi, Innovent Biologics, Inc., Intas Pharmaceuticals Ltd., Kashiv BioSciences, LLC., Merck & Co., Inc., NeuClone, Nippon Kayaku Co., Ltd., Novartis AG, Panacea Biotec Limited, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific, Inc..
This research report categorizes the Biosimilars Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Product
- Recombinant Glycosylated Proteins
- Erythropoietin
- Follitropin
- Monoclonal Antibodies
- Adalimumab
- Infliximab
- Rituximab
- Recombinant Non-Glycosylated Proteins
- Granulocyte Colony-Stimulating Factor
- Insulin
- Interferons
- Interferon-Alpha
- Interferon-Beta
- Recombinant Human Growth Hormone
- Recombinant Peptides
- Calcitonin
- Glucagon
- Recombinant Glycosylated Proteins
- Indication
- Autoimmune Diseases
- Blood Disorders
- Chronic Diseases
- Growth Hormone Deficiency
- Infectious Diseases
- Oncology
- Manufacturing
- Contract Manufacturing
- In-House Manufacturing
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Biosimilars Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biosimilars Market?
- What are the technology trends and regulatory frameworks in the Biosimilars Market?
- What is the market share of the leading vendors in the Biosimilars Market?
- Which modes and strategic moves are suitable for entering the Biosimilars Market?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Biosimilars Market, by Product
- Biosimilars Market, by Indication
- Biosimilars Market, by Manufacturing
- Americas Biosimilars Market
- Asia-Pacific Biosimilars Market
- Europe, Middle East & Africa Biosimilars Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 22]
- List of Tables [Total: 738]
- List of Companies Mentioned [Total: 28]
- How big is the Biosimilars Market?
- What is the Biosimilars Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?